Diversity in clinical trials must be accompanied by justice and equity, including benefits for underrepresented participants, in order to boost population health.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
15 April 2024
The version of this article initially published was an uncorrected proof; it has now been replaced by the final version.
References
US Department of Health and Human Services. The Belmont Report https://go.nature.com/3mj33xy (2010).
Baptiste, D.-L. et al. Nursing Open 9, 2236 (2022).
Pacheco, C. M. et al. Am. J. Public Health 103, 2152–2159 (2013).
Ndugga, N., Pillai, D. & Artiga, S. Racial and Ethnic Disparities in Access to Medical Advancements and Technologies. https://go.nature.com/4arFv7b (2024).
Breathett, K. & Manning, K. D. Circ. Cardiovasc. Qual. Outcomes 17, e010009 (2024).
Cullen, M. R. et al. Contemporary Clinical Trials 129, 107184 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no conflicts of interest.
Rights and permissions
About this article
Cite this article
Breathett, K. Why diversity is needed at every level of clinical trials, from participants to leaders. Nat Med 30, 929 (2024). https://doi.org/10.1038/s41591-024-02914-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-024-02914-x
